Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Gerlach, J.
Reisby, N.
and
Randrup, A.
1974.
Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia.
Psychopharmacologia,
Vol. 34,
Issue. 1,
p.
21.
KURLAND, ALBERT A.
OTA, KAY Y.
and
SLOTNICK, VICTOR B.
1975.
Penfluridol: A Long‐Acting Oral Neuroleptic..
The Journal of Clinical Pharmacology,
Vol. 15,
Issue. 8-9,
p.
611.
Simpson, George M.
Varga, Ervin
Lee, J. Hillary
and
Zoubok, Boris
1978.
Tardive dyskinesia and psychotropic drug history.
Psychopharmacology,
Vol. 58,
Issue. 2,
p.
117.
Gerlach, J.
and
Simmelsgaard, H.
1978.
Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.
Psychopharmacology,
Vol. 59,
Issue. 2,
p.
105.
Mackay, Angus V. P.
and
Sheppard, Graham P.
1979.
Pharmacotherapeutic Trials in Tardive Dyskinesia.
British Journal of Psychiatry,
Vol. 135,
Issue. 6,
p.
489.
Gibson, Alan C.
1979.
Questionnaire on Severe Tardive Dyskinesia.
British Journal of Psychiatry,
Vol. 134,
Issue. 5,
p.
549.
Fann, William E.
1980.
Tardive Dyskinesia.
p.
215.
Jeste, Dilip V
and
Wyatt, Richard Jed
1980.
Tardive Dyskinesia: A Review of the Treatment Possibilities.
Psychiatric Annals,
Vol. 10,
Issue. 1,
p.
26.
Jenner, P.
and
Marsden, C.D.
1982.
Drugs in Psychiatric Practice.
p.
82.
Yassa, R.
1985.
Antiparkinsonian Medication Withdrawal in the Treatment of Tardive Dyskinesia: A Report of Three Cases.
The Canadian Journal of Psychiatry,
Vol. 30,
Issue. 6,
p.
440.
Ahrens, Thomas N.
Sramek, John J.
Herrera, John M.
Jewett, Christina M.
and
Alcorn, Velma E.
1988.
Pharmacy-Based Screening Program for Tardive Dyskinesia.
Drug Intelligence & Clinical Pharmacy,
Vol. 22,
Issue. 3,
p.
205.
Cummings, Jeffrey L.
and
Wirshing, William C.
1990.
Recognition and Differential Diagnosis of Tardive Dyskinesia.
The International Journal of Psychiatry in Medicine,
Vol. 19,
Issue. 2,
p.
133.
Glazer, William M.
Morgenstern, Hal
and
Doucette, John T.
1991.
The Prediction of Chronic Persistent Versus Intermittent Tardive Dyskinesia.
British Journal of Psychiatry,
Vol. 158,
Issue. 6,
p.
822.
Muscettola, G.
Pampallona, S.
Barbato, G.
Casiello, M.
Bollini, P.
and
Muscettola, Giovanni
1993.
Persistent tardive dyskinesia: demographic and pharmacological risk factors.
Acta Psychiatrica Scandinavica,
Vol. 87,
Issue. 1,
p.
29.
McGrath, JJ
Soares-Weiser, KVS
and
McGrath, John
1998.
The Cochrane Database of Systematic Reviews.
Soares-Weiser, Karla
and
Rathbone, John
2006.
Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Cochrane Database of Systematic Reviews,
Matson, Johnny L.
and
Mahan, Sara
2010.
Antipsychotic drug side effects for persons with intellectual disability.
Research in Developmental Disabilities,
Vol. 31,
Issue. 6,
p.
1570.
Caroff, Stanley N.
Ungvari, Gabor S.
and
Cunningham Owens, David G.
2018.
Historical perspectives on tardive dyskinesia.
Journal of the Neurological Sciences,
Vol. 389,
Issue. ,
p.
4.
Bergman, Hanna
Rathbone, John
Agarwal, Vivek
and
Soares-Weiser, Karla
2018.
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.
Cochrane Database of Systematic Reviews,
Vol. 2018,
Issue. 2,
Caroff, Stanley N.
2020.
Recent Advances in the Pharmacology of Tardive Dyskinesia.
Clinical Psychopharmacology and Neuroscience,
Vol. 18,
Issue. 4,
p.
493.
eLetters
No eLetters have been published for this article.